T1	p 326 341	breast cancer .
T2	p 490 502	chemotherapy
T3	p 507 513	breast
T4	p 846 875	patients with breast cancer .
T5	p 1117 1170	age of the 94 women was 51 years ( range 27-76 ) : 79
T6	p 1237 1265	doxorubicin/cyclophosphamide
T7	p 1268 1285	Thirteen withdrew
T8	i 32 50	placebo-controlled
T9	i 115 128	dexamethasone
T10	i 151 172	adjuvant chemotherapy
T11	i 364 377	dexamethasone
T12	i 543 567	dexamethasone or placebo
T13	i 757 782	oral dexamethasone ( 4 mg
T14	i 815 822	placebo
T15	i 910 977	granisetron and dexamethasone pre-chemotherapy and oral granisetron
T16	i 1237 1267	doxorubicin/cyclophosphamide .
T17	i 1384 1391	placebo
T18	i 1467 1480	dexamethasone
T19	i 1676 1691	dexamethasone .
T20	i 1862 1886	dexamethasone or placebo
T21	i 1911 1925	chemotherapy .
T22	o 85 100	quality of life
T23	o 274 280	nausea
T24	o 285 293	vomiting
T25	o 600 660	nausea and vomiting , and to compare quality of life ( QOL )
T26	o 1020 1040	patient preference ;
T27	o 1046 1047	)
T28	o 1084 1090	of QOL
T29	o 1535 1598	intensity of vomiting , nausea , or time to onset of vomiting .
T30	o 1629 1639	global QOL
T31	o 1695 1720	other symptom/QOL domains
T32	o 1801 1839	patient preference , QOL , or symptoms